|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003316,
umls-concept:C0006141,
umls-concept:C0033572,
umls-concept:C0033684,
umls-concept:C0039195,
umls-concept:C0086418,
umls-concept:C0205314,
umls-concept:C0679622,
umls-concept:C0960676,
umls-concept:C1512505,
umls-concept:C2349975
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2004-4-2
|
|
pubmed:abstractText |
Vaccine therapy for prostate and breast cancer may have potential for treating these major causes of death in males and females, respectively. Critical to the development of tumor-specific vaccines is finding and characterizing novel antigens to be recognized by CD8(+) T cells. To define new CD8(+) T-cell tumor antigens, we determined two wild-type HLA-A2 epitopes from a recently found tumor-associated protein, TARP (T-cell receptor gamma alternate reading frame protein), expressed in prostate and breast cancer cells. We were also able to engineer epitope-enhanced peptides by sequence modifications. Both wild-type and enhanced epitopes induced peptide-specific CD8(+) T-cell responses in A2K(b) transgenic mice. In vitro restimulation of human CD8(+) T cells from a prostate cancer patient resulted in CD8(+) T cells reactive to the peptide epitopes that could lyse HLA-A2(+) human breast cancer cells (MCF-7) expressing TARP. Epitope-specific human CD8(+) T cells were also enumerated in patients' peripheral blood by tetramer staining. Our data suggest that HLA-A2-binding TARP epitopes and enhanced epitopes discovered in this study could be incorporated into a potential vaccine for both breast and prostate cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0008-5472
|
|
pubmed:author |
pubmed-author:BeraTapan KTK,
pubmed-author:BerzofskyJay AJA,
pubmed-author:BhattacharyyaAnuA,
pubmed-author:EpelMalkaM,
pubmed-author:Kasten-SportesClaudeC,
pubmed-author:LinehanW MarstonWM,
pubmed-author:OhSangKonS,
pubmed-author:PastanIraI,
pubmed-author:PendletonC DavidCD,
pubmed-author:PhillipsJohnJ,
pubmed-author:ReiterYoramY,
pubmed-author:TerabeMasakiM
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
64
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2610-8
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15059918-Amino Acid Sequence,
pubmed-meshheading:15059918-Animals,
pubmed-meshheading:15059918-Breast Neoplasms,
pubmed-meshheading:15059918-Cancer Vaccines,
pubmed-meshheading:15059918-Epitopes, T-Lymphocyte,
pubmed-meshheading:15059918-Female,
pubmed-meshheading:15059918-HLA-A2 Antigen,
pubmed-meshheading:15059918-Humans,
pubmed-meshheading:15059918-Lymphocyte Activation,
pubmed-meshheading:15059918-Male,
pubmed-meshheading:15059918-Mice,
pubmed-meshheading:15059918-Mice, Inbred C57BL,
pubmed-meshheading:15059918-Mice, Transgenic,
pubmed-meshheading:15059918-Molecular Sequence Data,
pubmed-meshheading:15059918-Nuclear Proteins,
pubmed-meshheading:15059918-Peptide Fragments,
pubmed-meshheading:15059918-Prostatic Neoplasms,
pubmed-meshheading:15059918-T-Lymphocytes, Cytotoxic
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells.
|
|
pubmed:affiliation |
Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-1578, USA.
|
|
pubmed:publicationType |
Journal Article
|
